Kaneka's Q1 Operating Profit Jumps 83%, but the Full-Year Forecast Is Left Unchanged

All four units grew sales and profit

Kaneka Corporation (TSE: 4118), the Japanese chemicals group whose four solution units span vinyls and modifier resins, foam insulation, optical and polyimide film, solar cells, artificial hair fibre, blood-purification devices and catheters, and coenzyme Q10 supplements, published consolidated results for the three months to June 30, 2026 on August 13, 2026 under Japanese GAAP. Revenue rose 12.3% to ¥223,025 million, operating profit 83.1% to ¥14,944 million, ordinary profit 127.7% to ¥13,750 million and net profit attributable to owners of the parent 109.8% to ¥8,941 million, for basic earnings per share of ¥148.46 against ¥67.74 and diluted earnings of ¥147.90 against ¥67.53. Comprehensive income was ¥11,129 million, up 143.7%. The company says every unit grew both sales and profit and that the quarter exceeded the fourth quarter that preceded it.

This is a margin story rather than a volume one. Gross profit rose 21.0% to ¥65,579 million on 12.3% more revenue, so the gross margin widened from 27.3% to 29.4%, while selling, general and administrative expenses grew 10.0% to ¥50,635 million. The operating margin therefore went from 4.1% to 6.7%. Management's account matches the numbers: it describes responding to the disruption of the petrochemical supply chain that followed heightened tension in the Middle East, and says it met rising raw-material costs by revising prices, having put procurement and supply capability — logistics included — first so that those revisions could be made at all. Price revision is named as a driver in the write-up of every one of the four units.

Material Solutions supplied two thirds of the profit increase

Material Solutions is the largest unit and did most of the work. Its revenue rose 14.7% to ¥94,444 million, half of the group's ¥24,343 million revenue increase, and its segment profit 73.3% to ¥10,858 million — ¥4,593 million of the group's ¥6,783 million operating-profit increase, or 67.7% of it — lifting the unit's margin from 7.6% to 11.5%. Quality of Life Solutions grew revenue 11.1% to ¥53,849 million and profit 34.5% to ¥7,006 million. Nutrition Solutions grew revenue 6.3% to ¥52,434 million and profit 25.5% to ¥3,363 million. Health Care Solutions was fastest on the top line, up 20.5% to ¥22,026 million, but is the one unit whose margin fell: profit rose 11.3% to ¥3,486 million, so the margin slipped from 17.1% to 15.8%.

The unit commentary explains the shape. Health Care was carried by Medical — blood purifiers and catheters both sold more, and the acquired EndoStream and Zeon Medical businesses are described as beginning to contribute — while Pharma shipments were weak because sales had been concentrated in the previous fourth quarter. In Nutrition, reduced-form coenzyme Q10 sold sharply better in the United States and Asia, and Foods improved profitability by shifting toward higher value-added products. Within Quality of Life, optical film for large LCD televisions sold well while polyimide film was held back by production adjustment in the smartphone market. Two arithmetic points sit behind the headline: the four units and the small insurance-agency business together earned ¥24,855 million of segment profit against ¥17,415 million, a rise of only 42.7%, and the distance from there to the group's 83.1% is the unallocated corporate cost — mainly basic research and development — which grew just ¥656 million, to ¥9,910 million from ¥9,254 million. A near-fixed central cost is what turns a 42.7% segment gain into an 83.1% group one.

The currency line closed most of the gap to ordinary profit

Ordinary profit's 127.7% rise outruns operating profit's 83.1% because the non-operating drag more than halved. Operating profit of ¥14,944 million became ordinary profit of ¥13,750 million, a drag of ¥1,194 million against ¥2,123 million a year earlier. Currency did more than the whole ¥929 million improvement on its own: a ¥1,136 million foreign-exchange loss became a ¥336 million gain, a swing of ¥1,472 million, while interest expense rose to ¥1,094 million from ¥1,013 million, loss on disposal of fixed assets to ¥943 million from ¥723 million, and dividends received fell to ¥675 million from ¥832 million. Equity-method investment income was ¥54 million against ¥13 million. Below ordinary profit the direction reverses: there was no extraordinary gain this time against ¥1,075 million from the sale of investment securities a year ago, and litigation-related expense was ¥330 million against ¥261 million, so pre-tax profit rose 95.8% to ¥13,419 million, more slowly than ordinary profit. Earnings per share nevertheless grew 119.2%, faster than the 109.8% on attributable profit, because the average share count fell 4.3% to 60,227,163 from 62,909,810.

Inventories and borrowings rose, and the equity ratio slipped

Total assets rose ¥23,858 million to ¥983,013 million, which the company attributes to inventories and tangible fixed assets. Inventories went from ¥203,795 million to ¥218,330 million — finished goods of ¥117,616 million, work in process of ¥17,783 million and raw materials and supplies of ¥82,931 million — a build of ¥14,535 million in a quarter whose revenue rose ¥24,343 million. No quarterly cash-flow statement was prepared, so the cash effect is not disclosed; depreciation for the quarter was ¥12,064 million against ¥11,532 million and goodwill amortisation ¥105 million against ¥202 million. Liabilities rose ¥17,793 million to ¥455,278 million, on trade payables of ¥88,001 million against ¥81,006 million and short-term borrowings of ¥153,469 million against ¥139,531 million, while income taxes payable fell to ¥4,402 million from ¥9,480 million. Net assets rose only ¥6,064 million, to ¥527,734 million, so the equity ratio slipped to 51.3% from 52.0%. The consolidation scope changed by one company each way: Kaneka Korea Co., Ltd. was added and AB BIOTICS PTE. LTD. removed.

A quarter worth 41.5% of the year's operating target, inside an unchanged forecast

Full-year guidance for FY3/2027 is unchanged from the forecast published on May 14, 2026: revenue of ¥820,000 million (+1.0%), operating profit of ¥36,000 million (+9.4%), ordinary profit of ¥32,000 million (+10.8%) and net profit of ¥31,500 million (+1.7%), for earnings per share of ¥523.04. The arithmetic is awkward. Revenue is running at 27.2% of the annual figure, about a quarter's worth, but operating profit is already at 41.5% and ordinary profit at 43.0%; holding the operating target would take ¥21,056 million from the remaining nine months, roughly ¥7,019 million a quarter against the ¥14,944 million just delivered. The filing does address this, if not in those terms. It warns that the environment from the second quarter on remains unstable, says it assumes extremely high volatility, expects raw-material costs to keep rising in places and says it will keep working to defend spreads — and states plainly that the forecast will be revised and announced promptly once confidence in this year's outlook rises.

One feature of the guidance it does not explain is that guided net profit of ¥31,500 million sits within ¥500 million of guided ordinary profit of ¥32,000 million — a relationship this quarter's income statement, where ¥13,750 million of ordinary profit became ¥8,941 million attributable to the parent, does not show. Net profit is also the one guided line barely moving, at +1.7%, in a year whose operating and ordinary lines are guided up 9.4% and 10.8%. Against all of that, the dividend forecast is ¥210.00 a share — ¥105.00 at the interim and ¥105.00 at the year-end — against ¥160.00 paid for FY3/2026, a rise of 31.3%. That forecast is itself unchanged from the company's previous announcement, and the filing gives no reason for the step-up beyond leaving it in place.

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.